PDF-Guidance for Industry Assessment of Abuse Potential of Drugs DRAFT GUIDANCE This guidance

Federal Register Federal Register US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research CDER January 2010 Clinical Medical brPage 2br Guidance for Industry Assessment of Abuse Potential of Dr. 574115745557453574535744557454574605745957376574415745457444573765745957461574475744757445574595746057449574555745457459573765745857445574475744157458574445744957454574475737657460574485744957459573765744457458574415744657460573765744457455574435746 The Child Ab use Prevention and Treatment Act CAPTA has these definitions Child abuse and neglect At a minimum any recent act or failure to act o n the part of a parent or caretaker which results in death serious physical or emotional harm sexual a Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit written comments to the Di vision of Dockets Mana Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit electronic com ments to httpwwwregulationsgov Su Comments and suggestions regarding this draft document should be submitted within 60 calendar days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit comments to the Division of Dockets Mana Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit electronic comments on the draft guidance to http Comments and suggestions regarding this draft document should be submitted within 60 calendar days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit comments to the Division of Dockets Mana Federal Register Federal Register US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research CDER March 2014 ClinicalMedical 16617dftdoc 030614 brPage 2br Guidance for Industry Chronic Fatigue Sy Additional copies are available from: Office of Training and Communications Division of Drug Information, HFD-240 Center for Drug Evaluation and Research Food and Drug Administration 10903 New Hampshi 10302dft.doc 08/06/12 Additional copies are available from: Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 10903 New Hampsh 11157dft.doc 07/29/15 Additional copies are available from: Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 10001 New Hamps 15028dft.doc 07/27/16 Additional copies are available from: Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 10001 New Hampsh G:\5412dft.doc01/02/03 G:\5412dft.doc01/02/03 The Division of Drug Information (HFD-240)Center for Drug Evaluation and Research (Tel) 301-827-4573 Draft — Not for ImplementationG:\5412dft.doc01/0 Standing Committee on Finance . Presenters: National Treasury and SARS | 14 September 2017. Consultation process. The 2017 Draft Taxation Laws Amendment Bill (TLAB) and 2017 Draft Tax Administration Laws Amendment Bill (TALAB) were published for public comment on 19.